share_log
  • Headlines
  • Ideaya Biosciences Has Dosed The First Patient In Phase 1 Trial Evaluating The Combination Of IDE161 In Combination With Merck's Keytruda (Pembrolizumab), In Endometrial Cancer Patients With High Microsatellite Instability And Microsatellite Stable

Ideaya Biosciences Has Dosed The First Patient In Phase 1 Trial Evaluating The Combination Of IDE161 In Combination With Merck's Keytruda (Pembrolizumab), In Endometrial Cancer Patients With High Microsatellite Instability And Microsatellite Stable

Benzinga ·  Dec 10, 2024 19:06
  • First patient dosed with combination of IDE161, IDEAYA's investigational, potential first-in-class PARG inhibitor, in combination with KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy
  • The IDEAYA-sponsored Phase 1 clinical trial will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of IDE161 in combination with KEYTRUDA in patients with MSI-high and MSS endometrial cancer
  • Selected initial Phase 1/2 expansion dose for IDE161 monotherapy in a priority solid tumor type, based on AE profile and preliminary clinical efficacy observed
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment
    Heat List
    US
    SymbolLatest Price% Chg

    No Data

    Hot News
    Updated